U.K., EU eye FDA's findings on Ranbaxy plant; J&J psoriasis med poised for $1.4B in 2014; Ohio docs fined for importing unapproved cancer meds;

@FiercePharma: Our newest publication, FiercePharmaMarketing, is now live at fiercepharmamarketing.com. All marketing, all the time. | Follow @FiercePharma

@TracyStaton: FDA approval, check. Now Teva has to woo patients to new longer-acting Copaxone. Story | Follow @TracyStaton

@EricPFierce: Lilly announced 1,000 job cuts in 2013. 2014 expected to be even bleaker. Report | Follow @EricPFierce

@CarlyHFierce: And here's the rundown from @TracyStaton on what the new pub has in store. Item | Follow @CarlyHFierce

> EU and U.K. regulators are reviewing the FDA's findings on Ranbaxy's Toansa plant, subject of the latest enforcement action by the U.S. agency. Report

> Decision Resources figures that Johnson & Johnson's ($JNJ) new psoriasis drug Stelara will leap to the front of the line among systemic treatments, with $1.4 billion in sales next year. Release

> Seven Ohio oncologists were ordered to pay nearly $2.6 million in fines for importing unapproved cancer drugs into the U.S. Report

> Ireland's Minister for Finance plans to meet with top Regeneron ($REGN) executives in New York this week about a planned €220 million investment in the country. Report

> Novo Nordisk ($NVO) and a group of London hospitals are teaming up to develop a new model of patient-centered, specialty diabetes management. Report

Medical Device News

@FierceMedDev: Hydrogel with tiny capsules could control the release of drugs. More from FierceDrugDelivery | Follow @FierceMedDev

@MichaelGFierce: Nanodiamonds covered in silk promise smoother drug delivery. Story | Follow @MichaelGFierce

@EmilyWFierce: GenePeeks lets women get a closer look at potential donors' DNA, predict risk for disease in hypothetical child. Article | Follow @EmilyWFierce

@GalenMoore: Wait times for a doctor's appointment are longest in Boston, shortest in Dallas, survey says. Survey | Follow @GalenMoore

> Abbott slashes jobs at corporate headquarters. More

> Illumina's sales soar 24% with sights set on a big 2014. Story

> Medtronic's stent graft follows Gore's into aortic dissections with FDA approval. News

Biotech News

@FierceBiotech: IPO hopefuls look to extend biotech's window with $123M in fresh pitches. More | Follow @FierceBiotech

@JohnCFierce: Amgen extends PhIII sweep with more promising results for PCSK9 drug. Story | Follow @JohnCFierce

@DamianFierce: Novartis races to the FDA with its 'breakthrough' lung cancer drug. More | Follow @DamianFierce

@EmilyMFierce: Yesterday's issue of FierceBiotech Research featured microbiota and virus-free stem cells. Check it out here. | Follow @EmilyMFierce

> AstraZeneca is cutting 168 jobs as it shutters an Indian R&D site. News

> Merck's allergy pill sways an FDA panel but faces a long road to success. Article

Drug Delivery News

> Hydrogel with tiny capsules could control the release of drugs. Story

> URI scientist collects $1.3M to blast tumors with nanoparticles. More

> Nanodiamonds covered in silk promise smoother drug delivery. Article

> Nanogold 'superstructures' are held together with DNA for cancer drug delivery. News

> Evoke Pharma's nasal spray outdoes oral generic for diabetes-related stomach disease. Piece

> Artificial pancreas news: U.K. researchers unveil device, Animas snags Canadian approval of closed-loop system. Item

Diagnostics News

> Fluidigm is acquiring DVS in a $208M single-cell technology buyout. Story

> MDxHealth teams up with Teva to distribute its prostate, brain cancer tests. Article

> Will the real $1,000 genome please stand up? Story

> Epic Sciences teams with LabCorp to push its cancer diagnostic. News

> Nanostring grabs $55M in a follow-on offering. Article

> DioGenix's multiple sclerosis test hits the mark in a study. Item

Pharma Marketing News

> J&J persuades LA Supreme Court to toss $257M Risperdal marketing verdict. Story

> FDA approval, check. Now Teva has to woo patients to new, longer-acting Copaxone. News

> J&J tops 2013 journal-ad ranks with millions in print support for Invokana, Xarelto. Article

> Vivus, Arena hope Aetna weight-management program boosts diet-drug sales. Piece

> Priligy maker Menarini puts rugby players on cinema screens in premature-ejaculation awareness push. Item

And Finally... Belgium's UCB has launched a competition to find "superhumans" with unusual characteristics, believing genetic differences could identify new drug-development targets. Report

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.